Guangzhou Baiyunshan Pharmaceutical Holdings Branch obtained the Macao Generic Drug Registration Certificate for Cefradine Capsules.

Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) has announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Holdings pharmaceutical group Co., Ltd. (referred to as "Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceuticals Factory"), has received the registration certificate for Ceftazidime capsules from the Macao Special Administrative Region Government's Drug Regulatory Authority. It is reported that Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceuticals Factory submitted the application for the registration of Ceftazidime capsules 0.125g to the Macao Special Administrative Region Government's Drug Regulatory Authority on June 1, 2026, and received pre-approval acceptance on June 22, 2026. Ceftazidime capsules are used for respiratory tract infections such as acute tonsillitis, pharyngitis, otitis media, sinusitis, bronchitis, pneumonia, urinary tract infections, and skin and soft tissue infections caused by sensitive bacteria. The medication is for oral administration and should not be used for severe infections.